The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Open accessAbstract
BACKGROUND: The combination of cyclophosphamide and glucocorticoids leads to remission in most patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitides. However, even when patients receive maintenance treatment with azathioprine or methotrexate, the relapse rate remains high. Rituximab may help to maintain remission. METHODS: Patients with newly diagnosed or relapsing granulomatosis with polyangiitis, microscopic polyangiitis, or renal-limited ANCA-associated vasculitis in complete remission after a cyclophosphamide-glucocorticoid regimen were randomly assigned to receive either 500 mg of rituximab on days 0 and 14 and at months 6, 12, and 18 after study entry or daily azathioprine until month 22. The primary end point at month 28 was the rate of major relapse (the reappearance of disease activity or worsening, with a Birmingham Vasculitis Activity Score >0, and involvement of one or more major organs, disease-related life-threatening events, or both). RESULTS: The 115 enrolled patients (87 with granulomatosis with polyangiitis, 23 with microscopic polyangiitis, and 5 with renal-limited ANCA-associated vasculitis) received azathioprine (58 patients) or rituximab (57 patients). At month 28, major relapse had occurred in 17 patients in the azathioprine group (29%) and in 3 patients in the rituximab group (5%) (hazard ratio for relapse, 6.61; 95% confidence interval, 1.56 to 27.96; P=0.002). The frequencies of severe adverse events were similar in the two groups. Twenty-five patients in each group (P=0.92) had severe adverse events; there were 44 events in the azathioprine group and 45 in the rituximab group. Eight patients in the azathioprine group and 11 in the rituximab group had severe infections, and cancer developed in 2 patients in the azathioprine group and 1 in the rituximab group. Two patients in the azathioprine group died (1 from sepsis and 1 from pancreatic cancer). CONCLUSIONS: More patients with ANCA-associated vasculitides had sustained remission at month 28 with rituximab than with azathioprine. (Funded by the French Ministry of Health; MAINRITSAN ClinicalTrials.gov number, NCT00748644; EudraCT number, 2008-002846-51.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
Jennette, J. C., Falk, R. J., Bacon, P. A., Basu, N., Cid, M. C., Ferrario, F., Flores‐Suarez, L. F., Gross, W. L., Guillevin, L., Hagen, E. C., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37715 · Cited by 6,631
Self-citationRituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Jones, R. B., Cohen Tervaert, J. W., Hauser, T., Luqmani, R., Morgan, M. D., Peh, C. A., Savage, C. O., Segelmark, M., Tesar, V., van Paassen, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909169 · Cited by 1,748
Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020286 · Cited by 1,348
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
Kallenberg, C. G. M., Lamprecht, P., Hoffman, G. C., Rasmussen, N., Pusey, C. D., Özen, S., Matteson, E. L., Merkel, P. A., Flores-Suarez, L. F., Bacon, P. A., et al. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/tnnw-jw94 · Cited by 1,255
Self-citationde Groot, K., Harper, L., Jayne, D. R. W., Flores Suarez, L. F., Gregorini, G., Gross, W. L., Luqmani, R., Pusey, C. D., Rasmussen, N., Sinico, R. A., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-10-200905190-00004 · Cited by 957
De Groot, K., Rasmussen, N., Bacon, P. A., Tervaert, J. W. C., Feighery, C., Gregorini, G., Gross, W. L., Luqmani, R., & Jayne, D. R. W. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21142 · Cited by 801
Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
Specks, U., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Fessler, B. J., Ding, L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213277 · Cited by 728
Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis
Dhawan, R. (2009) · Yearbook of Medicine · doi:10.1016/s0084-3873(09)79350-2 · Cited by 674
Cyclophosphamide Therapy of Severe Systemic Necrotizing Vasculitis
Fauci, A. S., Katz, P., Haynes, B. F., & Wolff, S. M. (1979) · New England Journal of Medicine · doi:10.1056/nejm197908023010503 · Cited by 526
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Yates, M., Watts, R. A., Bajema, I. M., Cid, M. C., Crestani, B., Hauser, T., Hellmich, B., Holle, J. U., Laudien, M., Little, M. A., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209133 · Cited by 1,194
Self-citationKitching, A. R., Anders, H.-J., Basu, N., Brouwer, E., Gordon, J., Jayne, D. R., Kullman, J., Lyons, P. A., Merkel, P. A., Savage, C. O. S., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0204-y · Cited by 928
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
Hellmich, B., Sanchez-Alamo, B., Schirmer, J. H., Berti, A., Blockmans, D., Cid, M. C., Holle, J. U., Hollinger, N., Karadag, O., Kronbichler, A., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223764 · Cited by 768
Self-citationChung, S. A., Langford, C. A., Maz, M., Abril, A., Gorelik, M., Guyatt, G., Archer, A. M., Conn, D. L., Full, K. A., Grayson, P. C., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41773 · Cited by 702
Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., Hebert, V., Houivet, E., Calbo, S., Caillot, F., Golinski, M. L., Labeille, B., Picard-Dahan, C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30070-3 · Cited by 623
Groh, M., Pagnoux, C., Baldini, C., Bel, E., Bottero, P., Cottin, V., Dalhoff, K., Dunogué, B., Gross, W., Holle, J., et al. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.04.022 · Cited by 476
Self-citationANCA Glomerulonephritis and Vasculitis
Jennette, J. C., & Nachman, P. H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02500317 · Cited by 360
ANCA-associated vasculitis — clinical utility of using ANCA specificity to classify patients
Cornec, D., Gall, E. C.-L., Fervenza, F. C., & Specks, U. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.123 · Cited by 294
Unizony, S., Villarreal, M., Miloslavsky, E. M., Lu, N., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. M., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208073 · Cited by 267
B‐cell Therapy for Multiple Sclerosis: Entering an era
Greenfield, A. L., & Hauser, S. L. (2018) · Annals of Neurology · doi:10.1002/ana.25119 · Cited by 265
Caforio, A. L. P., Adler, Y., Agostini, C., Allanore, Y., Anastasakis, A., Arad, M., Böhm, M., Charron, P., Elliott, P. M., Eriksson, U., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx321 · Cited by 263
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Ebbo, M., Grados, A., Samson, M., Groh, M., Loundou, A., Rigolet, A., Terrier, B., Guillaud, C., Carra-Dallière, C., Renou, F., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0183844 · Cited by 253
Self-citationBalavoine, A.-S., Glinoer, D., Dubucquoi, S., & Wémeau, J.-L. (2015) · Thyroid® · doi:10.1089/thy.2014.0603 · Cited by 65
Favier, R., & Crépin, S. (2018) · Clinical Trials · doi:10.1177/1740774518760565 · Cited by 19
Physiopathologie de la granulomatose éosinophilique avec polyangéite (Churg-Strauss)
Chaigne, B., Dion, J., Guillevin, L., Mouthon, L., & Terrier, B. (2016) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2015.10.339 · Cited by 6
Self-citation
Metadata
- Authors
- Guillevin, L., Pagnoux, C., Karras, A., Khouatra, C., Aumaître, O., Cohen, P., Maurier, F., Decaux, O., Ninet, J., Gobert, P., Quémeneur, T., Blanchard-Delaunay, C., Godmer, P., Puéchal, X., Carron, P.-L., Hatron, P.-Y., Limal, N., Hamidou, M., Ducret, M., Daugas, E., Papo, T., Bonnotte, B., Mahr, A., Ravaud, P., & Mouthon, L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-06
- Volume
- 371
- Issue
- 19
- Pages
- 1771-1780
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2132820210
- Cited by
- 1,090
- References
- 27
- FWCI
- 64.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.